4.6 Article

Synthesis and Imaging Validation of [18F]MDL100907 Enabled by Ni-Mediated Fluorination

期刊

ACS CHEMICAL NEUROSCIENCE
卷 5, 期 7, 页码 611-615

出版社

AMER CHEMICAL SOC
DOI: 10.1021/cn500078e

关键词

[F-18]flourination; nickel-mediated; serotonin receptors; 5HT(2a); MDL100907; PET imaging

资金

  1. Department of Energy [DE-SC0008430]
  2. National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health
  3. NIH
  4. NIH [T90DA022759/R90DA023427]
  5. [S10RR017208]
  6. [S10RR026666]
  7. [S10RR022976]
  8. [S10RR019933]
  9. [S10RR02949S]
  10. U.S. Department of Energy (DOE) [DE-SC0008430] Funding Source: U.S. Department of Energy (DOE)

向作者/读者索取更多资源

Several voids exist in reliable positron emission tomography (PET) radioligands for quantification of the serotonin (5HT) receptor system. Even in cases where 5HT radiotracers exist, challenges remain that have limited the utility of 5HT imaging in clinical research. Herein we address an unmet need in 5HT(2a) imaging using innovative chemistry. We report a scalable and robust synthesis of [F-18]MDL100907, which was enabled by a Ni-mediated oxidative fluorination using [F-18]fluoride. This first demonstration of a Ni-mediated fluorination used for PET imaging required development of a new reaction strategy that ultimately provided high specific activity [F-18]MDL100907. Using the new synthetic strategy and optimized procedure, [F-18]MDL100907 was evaluated against [C-11]MDL100907 for reliability to quantify 5HT(2a), in the nonhuman primate brain and was found to be superior based on a single scan analysis using the same nonhuman primate. The use of this new 5HT(2a) racliotracer will afford clinical neuroscience research the ability to distinguish 5HT(2a) receptor abnormalities binding between healthy subjects and patients even when group differences are small.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据